Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Eleclazine, also known as GS-6615, is a selective late sodium current inhibitor. Eleclazine is potentially useful for treatment of coronary vasodilators, antiarrhythmics and vasodilators. Eleclazin showed a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart’s electrical cycle) in patients with long QT-3 (LQT3) syndrome. LQT3 is a genetic disorder that prolongs the heart’s QTc interval and can cause life-threatening cardiac arrhythmias (abnormal heartbeats).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 35 days | $ 65.00 | |
10 mg | 35 days | $ 123.00 | |
25 mg | 35 days | $ 290.00 | |
50 mg | 35 days | $ 497.00 |
Description | Eleclazine, also known as GS-6615, is a selective late sodium current inhibitor. Eleclazine is potentially useful for treatment of coronary vasodilators, antiarrhythmics and vasodilators. Eleclazin showed a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart’s electrical cycle) in patients with long QT-3 (LQT3) syndrome. LQT3 is a genetic disorder that prolongs the heart’s QTc interval and can cause life-threatening cardiac arrhythmias (abnormal heartbeats). |
Molecular Weight | 415.37 |
Formula | C21H16F3N3O3 |
CAS No. | 1443211-72-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Eleclazine free base 1443211-72-0 SCR-1693 Eleclazine SCR1693 inhibitor inhibit